Interferons in Systemic Lupus Erythematosus

Sirisha Sirobhushanam; Stephanie Lazar; J Michelle Kahlenberg

doi:10.1016/j.rdc.2021.04.001

Interferons in Systemic Lupus Erythematosus

Rheum Dis Clin North Am. 2021 Aug;47(3):297-315. doi: 10.1016/j.rdc.2021.04.001. Epub 2021 Jun 10.

Authors

Sirisha Sirobhushanam¹, Stephanie Lazar¹, J Michelle Kahlenberg²

Affiliations

¹ Department of Internal Medicine, Division of Rheumatology, University of Michigan, 5568 MSRB 2, 1150 West Medical Center Drive, Ann Arbor, MI 49109, USA.
² Department of Internal Medicine, Division of Rheumatology, University of Michigan, 5570A MSRB 2, 1150 West Medical Center Drive, Ann Arbor, MI 49109, USA; Department of Dermatology, University of Michigan, 5570A MSRB 2, 1150 West Medical Center Drive, Ann Arbor, MI 49109, USA. Electronic address: mkahlenb@med.umich.edu.

Abstract

Skewing of type I interferon (IFN) production and responses is a hallmark of systemic lupus erythematosus (SLE). Genetic and environmental contributions to IFN production lead to aberrant innate and adaptive immune activation even before clinical development of disease. Basic and translational research in this arena continues to identify contributions of IFNs to disease pathogenesis, and several promising therapeutic options for targeting of type I IFNs and their signaling pathways are in development for treatment of SLE patients.

Keywords: Interferon; JAK; Lupus; STAT.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Review

MeSH terms

Humans
Interferon Type I*
Interferons
Lupus Erythematosus, Systemic* / drug therapy
Signal Transduction

Substances

Interferon Type I
Interferons

Abstract

Publication types

MeSH terms

Substances

Grants and funding